MidLantic Urology
Welcome,         Profile    Billing    Logout  
 3 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moreno, Jose C
NCT04740671 / 2020-005364-57: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Active, not recruiting
3
388
Europe, US, RoW
HLX04-O, ranibizumab
Shanghai Henlius Biotech
Age Related Macular Degeneration
12/24
03/25
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
07/24
08/24
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Recruiting
2
138
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
08/25
08/25
NCT05032196: Study of WVE-003 in Patients With Huntington's Disease

Recruiting
1/2
54
Europe, Canada, RoW
WVE-003
Wave Life Sciences Ltd.
Huntington Disease
12/24
12/24
CHARTER, NCT05437679: Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Terminated
N/A
9
US
Blood collection, Data collection
Angle plc, MidLantic Urology, LLC
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
08/23
08/23
Zinar, Cheryl
NCT05799248: Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Recruiting
3
113
US
rhPSMA-7.3 (18F), radiohybrid PSMA-targeted PET imaging agent, Radioligand for PET CT scanning
MidLantic Urology, Blue Earth Diagnostics
Prostate Cancer
05/24
05/24
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
PRL-02-1001, NCT04729114: Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Recruiting
1/2
100
US
PRL-02 injection, prednisone, dexamethasone, docetaxel infusion
Astellas Pharma Global Development, Inc.
Prostate Cancer, mCRPC, mCSPC
12/24
04/25
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Active, not recruiting
N/A
196
US
Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy
Applaud Medical, Inc.
Urinary Stones
06/23
08/24
CHARTER, NCT05437679: Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Terminated
N/A
9
US
Blood collection, Data collection
Angle plc, MidLantic Urology, LLC
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
08/23
08/23
NCT05250908: INTIBIA Pivotal Study

Recruiting
N/A
225
Europe, US
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Coloplast A/S
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
03/24
03/25

Download Options